Re-Vana Therapeutics Ltd, a Belfast, Northern Eire, UK-based specialty drug supply firm creating sustained-release therapeutics for the therapy of vision-threatening ocular ailments, closed its Collection A spherical with $11.9m in funding.
The spherical was led by Visionary Ventures with participation from ExSight Ventures, InFocus Capital Companions and current U.Ok. buyers, Qubis Ltd, Co-Fund NI, and TechStart Ventures. Together with this financing, Re-Vana’s board of administrators has been additional strengthened by the appointments of Robert Avery, M.D., of Visionary Ventures and InFocus Capital Companions, as board member, and Michael O’Rourke, President and CEO of Re-Vana Therapeutics, as Board Chair.
The corporate intends to make use of the proceeds for the event of its novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD™ and OcuLief® biodegradable drug supply applied sciences and for the growth of operations and improvement groups.
Based in 2016 as a spin-out from Queen’s College Belfast, Northern Eire, Re-Vana Therapeutics is a specialty ocular therapeutic and drug supply firm with headquarters positioned in Belfast and a U.S.-based workplace, Re-Vana Therapeutics, Inc., in Tampa, Florida. it’s at present creating sustained launch ophthalmic therapeutics geared toward lowering the frequency of intravitreal injections required to deal with a variety of retinal ailments, together with neovascular age-related macular degeneration (moist AMD). As well as, its proprietary photo-crosslinked sustained-release know-how might allow the event of a broad vary of novel, sustained launch merchandise relevant to quite a lot of therapeutic areas.